Alimera Sciences, Inc.
| Nasdaq: ALIM
Alimera Sciences, Inc. is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. It focuses on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies. Alimera Sciences was founded on June 4, 2003 by C. Daniel Myers and David R. Holland and is headquartered in Alpharetta, GA.